Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012

  //health-fitness.news-articles.net/content/2012/ .. ncial-results-conference-call-on-may-8-2012.html
  Published in Health and Fitness on Monday, April 30th 2012 at 16:46 GMT by Market Wire
          ^{🞛 This publication is a summary or evaluation of another publication}

Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8,... -- DUBLIN, April 30, 2012 /PRNewswire/ --

[ ]

My news for Investors

AtLeast one of the check box should be selected You are following news about Follow the latest news about JAZZ

DUBLIN, April 30, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: [ JAZZ ]) today announced that it will host a conference call and live webcast on Tuesday, May 8, 2012 at 4:30 p.m. EDT/9:30 p.m. IST. During the call, company management will provide a business and financial update and review first quarter 2012 results.

A live webcast of the presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at [ www.jazzpharmaceuticals.com ]. Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary to listen to the webcast.

Investors may participate in the conference call by dialing 800-573-4842 in the U.S., or 617-224-4327 outside the U.S., and entering passcode 95197533.

An archived version of webcast will be available for at least one week on the Investors section of the company's website at [ www.jazzpharmaceuticals.com ].

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: [ JAZZ ]) is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing products that address unmet medical needs.  The company has a diverse portfolio of products in the areas of narcolepsy, pain, psychiatry and women's health.  The company's marketed products in these areas include: Xyrem® (sodium oxybate), Prialt® (ziconotide intrathecal infusion), FazaClo® (clozapine USP) HD and LD, Luvox CR® (fluvoxamine maleate) and Elestrin^® (estradiol gel 0.06%).

SOURCE Jazz Pharmaceuticals plc

RELATED LINKS
[ http://www.jazzpharmaceuticals.com ]